Veracyte Inc (NAS:VCYT)
$ 31.57 1.15 (3.78%) Market Cap: 2.42 Bil Enterprise Value: 2.12 Bil PE Ratio: 0 PB Ratio: 2.14 GF Score: 83/100

Veracyte Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 14, 2021 / 07:30PM GMT
Release Date Price: $46.91 (-2.76%)
Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

Hey, everyone. Good afternoon. Thanks for joining us at our Healthcare Conference. I'm Tejas Savant, and I cover the Life Science Tools and Diagnostics sector here at Morgan Stanley. Delighted to have Veracyte join us today. And representing the Company are Marc Stapley, CEO; and Rebecca Chambers, CFO. Welcome to you both guys.

Before we begin, just some important disclosures I need to read out. Please see the Morgan Stanley Research Disclosure website at morganstanley.com/researchdisclosures. And if you have any questions, do reach out to your sales rep.

Marc, I believe you want to go through the safe harbor as well.

Marc A. Stapley
Veracyte, Inc. - CEO & Director

Yes. Thanks, Tejas, and appreciate you having us here. I'd like to remind everyone that all of today's comments are covered under our safe harbor statement, which can be found in our corporate presentation on the Investor page of our website at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot